Effect of Raltegravir Resistance Mutations in HIV-1 Integrase on Viral Fitness
- 1 October 2010
- journal article
- basic and-translational-science
- Published by Wolters Kluwer Health in JAIDS Journal of Acquired Immune Deficiency Syndromes
- Vol. 55 (2) , 148-155
- https://doi.org/10.1097/qai.0b013e3181e9a87a
Abstract
Raltegravir resistance is conferred by mutations at integrase codons 143, 148, and 155 together with associated secondary mutations. The N155H mutants emerge first, and are eventually replaced by Q148H mutants, usually in combination with G140S. These mutations have different effects on susceptibility and replication capacity, but data on the relative fitness of RAL-resistant viruses are limited. To understand the impact of the different RAL resistance pathways on viral fitness, mutations at integrase codons 74, 92, 138, 140, 148, 155, and/or 163 were introduced into HIV-1NL4-3 by site-directed mutagenesis and expressed in recombinant viruses. Relative fitness and drug susceptibility were determined in the absence or presence of RAL. In the absence of drug, RAL-resistant mutants were less fit than wild type, and the Q148H mutant was significantly less fit than the N155H mutant. Fitness was partially restored by the presence of additional RAL resistance mutations at positions G140S and E92Q or E138K, respectively. In the presence of RAL, the N155H mutant remained fitter than the Q148H mutant, but the G140S/Q148H double mutant was fitter than single mutants or the E92Q/N155H double mutant. These findings correspond well with the clinical trials data and help explain the temporal pattern of RAL resistance evolution.Keywords
This publication has 37 references indexed in Scilit:
- Impact of Y143 HIV-1 Integrase Mutations on Resistance to Raltegravir In Vitro and In VivoAntimicrobial Agents and Chemotherapy, 2010
- Loss of Raltegravir Susceptibility by Human Immunodeficiency Virus Type 1 Is Conferred via Multiple Nonoverlapping Genetic PathwaysJournal of Virology, 2009
- Selective-Advantage Profile of Human Immunodeficiency Virus Type 1 Integrase Mutants Explains In Vivo Evolution of Raltegravir Resistance GenotypesJournal of Virology, 2009
- Longitudinal Analysis of Raltegravir Susceptibility and Integrase Replication Capacity of Human Immunodeficiency Virus Type 1 during Virologic FailureAntimicrobial Agents and Chemotherapy, 2009
- In Vivo Fitness Cost of the M184V Mutation in Multidrug-Resistant Human Immunodeficiency Virus Type 1 in the Absence of LamivudineJournal of Virology, 2009
- Resistance Mutations in Human Immunodeficiency Virus Type 1 Integrase Selected with Elvitegravir Confer Reduced Susceptibility to a Wide Range of Integrase InhibitorsJournal of Virology, 2008
- In Vivo Emergence of Vicriviroc Resistance in a Human Immunodeficiency Virus Type 1 Subtype C-Infected SubjectJournal of Virology, 2008
- Viral Dynamics and In Vivo Fitness of HIV-1 in the Presence and Absence of EnfuvirtideJAIDS Journal of Acquired Immune Deficiency Syndromes, 2008
- Mutations Associated with Failure of Raltegravir Treatment Affect Integrase Sensitivity to the Inhibitor In VitroAntimicrobial Agents and Chemotherapy, 2008
- Fitness Comparison of Thymidine Analog Resistance Pathways in Human Immunodeficiency Virus Type 1Journal of Virology, 2006